- Home
- GAME vs RADX Comparison
GAME vs RADX Comparison
Compare GAME & RADX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GAME
- RADX
- Stock Information
- Founded
- GAME 2011
- RADX 2021
- Country
- GAME United States
- RADX Australia
- Employees
- GAME N/A
- RADX N/A
- Industry
- GAME
- RADX
- Sector
- GAME
- RADX
- Exchange
- GAME Nasdaq
- RADX NYSE
- Market Cap
- GAME 74.8M
- RADX 32.5M
- IPO Year
- GAME 2009
- RADX N/A
- Fundamental
- Price
- GAME $0.95
- RADX $4.81
- Analyst Decision
- GAME Strong Buy
- RADX Strong Buy
- Analyst Count
- GAME 3
- RADX 3
- Target Price
- GAME $3.67
- RADX $15.00
- AVG Volume (30 Days)
- GAME 25.4M
- RADX 18.6K
- Earning Date
- GAME 08-13-2025
- RADX 02-26-2025
- Dividend Yield
- GAME N/A
- RADX N/A
- EPS Growth
- GAME N/A
- RADX N/A
- EPS
- GAME N/A
- RADX N/A
- Revenue
- GAME $99,579,536.00
- RADX $204,609.00
- Revenue This Year
- GAME $6.08
- RADX N/A
- Revenue Next Year
- GAME $21.94
- RADX N/A
- P/E Ratio
- GAME N/A
- RADX N/A
- Revenue Growth
- GAME 77.06
- RADX N/A
- 52 Week Low
- GAME $0.50
- RADX $3.50
- 52 Week High
- GAME $2.87
- RADX $50.82
- Technical
- Relative Strength Index (RSI)
- GAME 42.61
- RADX N/A
- Support Level
- GAME $1.47
- RADX N/A
- Resistance Level
- GAME $1.24
- RADX N/A
- Average True Range (ATR)
- GAME 0.28
- RADX 0.00
- MACD
- GAME -0.10
- RADX 0.00
- Stochastic Oscillator
- GAME 0.07
- RADX 0.00
About GAME GameSquare Holdings Inc.
GameSquare Holdings Inc is engaged in revolutionizing the way brands and game publishers connect with hard-to-reach Gen Z, Gen Alpha, and Millennial audiences. It's next generation media, entertainment, and technology helps creators and maximize their brand partners' return on investment. Its purpose-built platform provides marketing and creative services, offers data and analytics solutions, and amplifies awareness through FaZe Clan.
About RADX RADIOPHARM THERANOSTICS LIMITED SPON ADS EACH REP 300 ORD
Radiopharm Theranostics Ltd is an Australian based clinical-stage radiotherapeutics company which is targeting cancer. The company has a pipeline of around four licensed platform technologies, with diagnostic and therapeutic applications in both pre-clinical and clinical stages of development. The company is engaged in research, development and commercialization of health technologies.